Galen Pharmaceuticals, a stock recently tipped as a good buy in this column, is attracting even greater attention, with brokers upgrading their long-term forecasts.

Riada has this week revised its forecasts strongly ahead for the next two years issuing a buy recommendation at the 337p level. The company has reported much stronger than expected full-year results and the shares are trading at the low-end of broker's forecasts.